CN103285473A - Oxytocin nasal spray - Google Patents
Oxytocin nasal spray Download PDFInfo
- Publication number
- CN103285473A CN103285473A CN2012100399972A CN201210039997A CN103285473A CN 103285473 A CN103285473 A CN 103285473A CN 2012100399972 A CN2012100399972 A CN 2012100399972A CN 201210039997 A CN201210039997 A CN 201210039997A CN 103285473 A CN103285473 A CN 103285473A
- Authority
- CN
- China
- Prior art keywords
- spray
- cylinder
- bottle
- inner bag
- oxytocin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101800000989 Oxytocin Proteins 0.000 title claims abstract description 46
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title claims abstract description 46
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title claims abstract description 43
- 229960001723 oxytocin Drugs 0.000 title claims abstract description 43
- 239000007922 nasal spray Substances 0.000 title claims abstract description 35
- 229940097496 nasal spray Drugs 0.000 title claims abstract description 35
- 239000007921 spray Substances 0.000 claims abstract description 92
- 235000002597 Solanum melongena Nutrition 0.000 claims abstract description 12
- 244000061458 Solanum melongena Species 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims description 31
- 239000003814 drug Substances 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000002699 waste material Substances 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000005507 spraying Methods 0.000 abstract 8
- 230000000052 comparative effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010021718 Induced labour Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000003191 uterotonic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
The invention provides an oxytocin nasal spray. A spraying device comprises a spraying bottle and a spraying head, and is characterized in that the spraying bottle comprises a casing (1) and a liner (2) with the volume of 6.0 ml; the liner of the spraying bottle is in a shape of a cylinder, the combination of a cylinder and an eggplant shape, or the combination of a cylinder, a sphere and a cylinder with a smaller diameter; the casing of the spraying bottle has the same appearance, size and connector part as those of a conventional 10 ml spray sold in the market; and the spraying head adopts a praying head of the conventional 10 ml spray sold in the market. The oxytocin nasal spray has the advantages of few residues, high safety and multiple effective spraying times, the production cost can be reduced, and the medicine waste is prevented.
Description
Technical field:
The present invention relates to a kind of oxytocin nasal spray, specifically relate to the oxytocin nasal spray that a kind of employing has the spray bottle of volume 6.0ml inner bag.
Background technology:
Oxytocin is to contain the peptide chain that 9 aminoacid of disulfide bond are formed, be the peptide hormone uterotonic, the main mechanism of action is to promote uterine smooth muscle to shrink, be hasten parturition clinically at present, the choice drug of induced labor, also be used in addition: 1, lactogenic, promote that puerperal, milk was discharged, improve breastfeeding rate, improve the milk output; 2, promote that puerperal, body recovered and the minimizing human milk silt, prevention mastitis and enclosed mass take place.
Oxytocin (1980) dosage form of going on the market abroad the earliest is injection, and the former producer of grinding is Novartis, trade name: Syntocinon, specification: 10 units/ml.The advantage of this injection: rapid-action (3.5 minutes) have the effect of significant contracting palace.Shortcoming: the pain of injection site makes many patients be difficult to accept after the administration.Because untoward reaction such as the feeling sick of pain stimulation, vomiting increase, patient's compliance is poor.
For overcoming the above-mentioned shortcoming of oxytocin inj, Novartis in 1980 is in U.S.'s oxytocin nasal spray that gone on the market, trade name: Syntocinon, specification: 40 units/ml.The Nasal Mucosa Absorption area is big, blood flow abundant, nasal spray passes through nasal mucosa medicine administration, has following advantage: can absorb blood and cerebrospinal fluid rapidly, medication is convenient, absorb fully, quantitatively accurately, absorb fast, damage is little, untoward reaction is little, safe ready, be easy to be accepted by the patient, thereby can be bigger the compliance of raising patient medication, so the oxytocin nasal spray is the dosage form of suitable clinical use.The mucosa delivery approach of peptide medicament comes into one's own just day by day at present.
The oxytocin nasal spray that Novartis produces, be with liquid medicine filling in common spray bottle, because the spray bottle volume is bigger, the medicinal liquid of smaller size smaller (5.0ml) is filled in the spray bottle, liquid level is lower, the degree of depth deficiency of submergence pipette, cause medicinal liquid to draw not exclusively, cause effectively spray inferior less, residual many, waste is big, though can solve effective hydrojet number of times defect of insufficient by the fill amount that strengthens medicinal liquid, but further strengthened the waste of expensive medicinal liquid, caused drug price high, strengthened patient's financial burden.
Summary of the invention:
Purpose of the present invention: overcome the defective that prior art exists, reduced waste, reduced the cost of oxytocin nasal spray, guarantee its safety and effectiveness simultaneously.Therefore, the invention provides the oxytocin nasal spray that a kind of employing has the spray bottle of volume 6.0ml inner bag.
For achieving the above object, basic design of the present invention be with the oxytocin liquid medicine filling in the spray bottle of an inner bag with less volume, described spray bottle comprises inside and outside two parts, and inner bag (2) is namely arranged in shell (1); Specifically see accompanying drawing 1,2,3.Shell (1) is all identical with profile, interface, the size of the spray bottle of prior art, thereby reaches the compatibility with existing fog-spray nozzle and filling production lines, need not to customize fog-spray nozzle and newly purchases production line, saves cost greatly; And inner bag (2) has smaller volume, is generally less than 10ml, and preferred 6.0ml is used for splendid attire 5.0ml oxytocin medicinal liquid, guarantees that dosage is accurate, residual little, safe, stops drug waste.
As the technical scheme that realizes the present invention's design, wherein be used for the spray bottle of fill oxytocin medicinal liquid, comprise shell and inner bag two parts, its structure is referring to accompanying drawing 1,2,3, preferably adopts accompanying drawing 2,3 inner bag shape, most preferably the inner bag shape of accompanying drawing 3.Wherein, in the accompanying drawing 1 inner bag be shaped as cylinder, bottle mouth position is wideer, need not accurate location in the time of can guaranteeing fill, the same easy operation with the common spray bottle of fill; The structure of inner bag is cylinder+eggplant shape inner bag in the accompanying drawing 2, with accompanying drawing about in the of 1 the consistent cylinder of diameter compare, termination one eggplant shape part under accompanying drawing 2 cylinders, fill need not accurate location except can be guaranteed the time, beyond the same easy operation with the common spray bottle of fill, be the oxytocin medicinal liquid of 5.0ml for fill volume, the top of the eggplant shape of accompanying drawing 2 bottleneck cylinder lower ends is the bigger hemisphere of diameter, the liquid level that can guarantee to load behind the medicinal liquid is unlikely to too near bottleneck, in order to avoid in the pouring process because the vibration of filling apparatus, cause medicinal liquid to spill, guarantee that fill dosage is accurate; Simultaneously tighten up eggplant shape inner bag lower end, even can guarantee spray through using, the residue medicine liquid volume hour, it is enough dark that the height of medicinal liquid liquid level still can submergence suction pipe entrance, thus medicinal liquid can be fully used.The inner-tube structure of accompanying drawing 3 is cylinder+spheroid+cylinder, wherein the hypomere cylinder of inner bag is the cylinder littler than epimere body diameter, further the hypomere cylinder of preferred inner bag partly is hemisphere near the cylinder tip at the bottle end, except the advantage with accompanying drawing 2 inner bags, the cylinder that its underpart diameter is littler can further improve the height of hour medicinal liquid liquid level of residue medicine liquid volume, and reduce the dead volume under the suction pipe entrance, can further improve the utilization rate of medicinal liquid.
The employed spray bottle of oxytocin nasal spray of the present invention, material can adopt general spray bottle commonly used medicinal plastics or glass, and processing mode both can inner bag and the shell one-shot forming of spray bottle, formation integral type spray bottle; Also can process inner bag separately, be shell with the common spray bottle of existing commercially available 10ml then, and the two is assembled into novel spray bottle of the present invention.A kind of processing mode in preferred back, reason be through industrially scalable repeatedly repeat research, we find preceding a kind of method (the shell one-shot forming that is inner bag and spray bottle is the integral type spray bottle) having relatively high expectations to mould, comparatively speaking, then there is not this problem in the processing inner bag separately, the inner bag mould structure is simple, required precision is identical with common medicine bottle, general conventional process operation can meet the demands, and can be as the common spray bottle of existing commercially available 10ml of shell, the producer of domestic capable production is numerous, in large supply, super quality and competitive price are lower on cost.
The employed spray bottle of oxytocin nasal spray of the present invention, its shell preferably has identical profile and size with the spray bottle of the common spray device of domestic commercially available 10ml, especially the interface section that is connected with sprayer unit (being commonly called as fog-spray nozzle), identical with the spray bottle interface of the high common spray device of 10ml of domestic market occupation rate, can pass through screw thread, bayonet socket or roll connecting devices commonly used such as mouthful aluminum cover and be connected with the fog-spray nozzle of the common spray device of domestic existing commercially available 10ml, thereby guarantee that container is airtight, medicinal liquid can not evaporate or leak, thereby makes oxytocin nasal spray of the present invention.Oxytocin pine nasal spray of the present invention with above-mentioned feature, its concrete embodiment can be referring to accompanying drawing 4 and accompanying drawing 5, fog-spray nozzle and spray bottle adopt screw thread to spin, wherein the inner bag shape of accompanying drawing 4 spray bottles is followed successively by cylinder+eggplant shape from top to bottom, the inner bag shape of accompanying drawing 5 spray bottles is followed successively by cylinder+sphere+cylinder from top to bottom, wherein the cylinder of hypomere is littler than epimere body diameter, and end portion is hemisphere.
Oxytocin nasal spray of the present invention, described sprayer unit is compared with the common spray device of existing commercially available 10ml, only be to have increased the inner bag part in common spray bottle inside, so when manufacturing except the mould part slight change, still can continue to use material and process equipment and the technology of original common spray device, need not special change.The fog-spray nozzle that this product adopts and the manufacturer of spray bottle is numerous, shipment amount is very big, thereby processing technique maturation, steady sources, low price, reliable in quality, pharmacy producer can obtain the cheap and good-quality source of goods; Simultaneously, the occupation rate of pharmacy producer is also quite high at home for the supporting common spray production line of 10ml with it, pharmacy producer can directly use the filling production lines of 10ml common aerosol to produce, need not to buy again new low capacity filling production lines, reduce the filling apparatus requirement of oxytocin nasal spray, saved cost.
Description of drawings
Fig. 1 is shaped as the inner bag of cylinder.
Fig. 2 is shaped as the inner bag of cylinder+eggplant shape.
Fig. 3 is shaped as the littler cylindrical inner bag of cylinder+spheroid+diameter.
Fig. 4 adopts the oxytocin nasal spray of the inner bag that is shaped as cylinder+eggplant shape.
Fig. 5 adopts the oxytocin nasal spray that is shaped as the littler cylindrical inner bag of cylinder+spheroid+diameter.
Wherein, Reference numeral is respectively: (1) shell, (2) inner bag
The specific embodiment
Following instantiation is illustrating of the specific embodiment of the invention, limits scope of the present invention but be not used in, and any embodiment that is equal to it is all within protection scope of the present invention.Wherein, except the comparative example, the spray bottle shell of embodiments of the invention all adopts with the spray bottle of the common spray device of domestic commercially available 10ml has identical profile and size and interface section, fog-spray nozzle all adopts the fog-spray nozzle (0.1ml/ spray) of the common spray device of domestic commercially available 10ml, and the inner bag volume is 6.0ml.
The comparative example:
(trade name: Syntocinon, manufacturer: Novartis), specification is 40 units/ml to oxytocin nasal spray commercially available product, 0.1ml/ spray, 5ml/ bottle.
Effectively hydrojet number of times and hydrojet residual rate test
Test method: get one of oxytocin nasal spray commercially available product, straight perpendicular holding, press shower nozzle examination spray and make its activation 4 times, clean nozzle, the accurate title, decide, continuous injection for several times (each injection interval 5 seconds) again, stop after the obvious minimizing of discharge rate, all clean nozzle and accurate the title after every spray once and decide installation weight, it is poor to calculate every spray front and back installation weight, be every spray discharge rate (mg), the hydrojet number of times before discharge rate obviously reduces is effective hydrojet number of times; Residue medicinal liquid in the spray bottle is taken out, and accurate the title, decide, and is the hydrojet residual quantity.
Computing formula:
Spray bottle herb liquid total amount=hydrojet residual quantity+each time discharge rate
Hydrojet residual rate=(hydrojet residual quantity/spray bottle herb liquid total amount) * 100%
Result of the test such as following table:
Table 1 comparative example hydrojet experimental result table
As follows according to above-mentioned formula result calculated:
Spray bottle herb liquid total amount=5362.6mg
Hydrojet residual rate=26.5%
Result of the test shows that 1～36 hydrojet weight of oxytocin nasal spray commercially available product is about 110mg, and the 37th time hydrojet weight obviously reduces, and is 72.4mg, thus its effectively spray time be 36 times, but the hydrojet residual rate is bigger, wastes more serious.
Embodiments of the invention
One, prescription (in 1000 bottles, the 0.1ml/ spray)
Two, preparation technology:
1. dosing: take by weighing in the water of supplementary material to 95% recipe quantity of recipe quantity, stir, make its dissolving, add the water standardize solution, namely.
2. fill: to the spray bottle shown in the accompanying drawing 2, every bottle of fill 5.0ml screws fog-spray nozzle (0.1ml/ spray) with the oxytocin aqueous solution fill of above-mentioned preparation, that is, final finished is seen accompanying drawing 4.
Three, effectively hydrojet number of times and hydrojet residual rate test
Test method: same comparative example
Computing formula: same comparative example
Result of the test such as following table:
Table 2 embodiment 1 hydrojet experimental result table
As follows according to above-mentioned formula result calculated:
Spray bottle herb liquid total amount=5380.8mg
Hydrojet residual rate=6.3%
Result of the test shows, 1～46 hydrojet weight of oxytocin nasal spray of embodiment 1 preparation is about 110mg, the 47th time hydrojet weight obviously reduces, be 68.6mg, therefore its effectively spray time be 46 times, under the situation of the medicinal liquid of comparative example's commercially available product fill equal volume, be higher than 36 times of commercially available product, the hydrojet residual rate is more much lower than commercially available product simultaneously, therefore greatly reduces patient's financial burden.
One, prescription (in 1000 bottles, the 0.1ml/ spray)
Two, preparation technology:
1. dosing: take by weighing in the water of supplementary material to 95% recipe quantity of recipe quantity, stir, make its dissolving, add the water standardize solution, namely.
2. fill: to the spray bottle shown in the accompanying drawing 3, every bottle of fill 5.0ml screws fog-spray nozzle (0.1ml/ spray) with the oxytocin aqueous solution fill of above-mentioned preparation, that is, final finished is seen accompanying drawing 5.
Three, effectively hydrojet number of times and hydrojet residual rate test
Test method: same comparative example
Computing formula: same comparative example
Result of the test such as following table:
Table 3 embodiment 2 hydrojet experimental result tables
As follows according to above-mentioned formula result calculated:
Spray bottle herb liquid total amount=5391.9mg
Hydrojet residual rate=2.4%
Result of the test shows, 1～48 hydrojet weight of oxytocin nasal spray of embodiment 1 preparation is about 110mg, the 49th time hydrojet weight obviously reduces, be 64.3mg, therefore its effectively spray time be 48 times, under the situation of the medicinal liquid of comparative example's commercially available product fill equal volume, be higher than 36 times of commercially available product, the hydrojet residual rate is more much lower than commercially available product simultaneously, has reduced patient's financial burden.
Claims (10)
1. an oxytocin nasal spray comprises medicinal liquid and sprayer unit, and used sprayer unit comprises spray bottle and fog-spray nozzle, it is characterized in that described spray bottle comprises the inner bag (2) of shell (1) and volume 6.0ml.
2. oxytocin nasal spray as claimed in claim 1 is characterized in that the inner bag of described spray bottle is shaped as cylinder or is followed successively by cylinder+eggplant shape from top to bottom.
3. oxytocin nasal spray as claimed in claim 1, the inner bag that it is characterized in that described spray bottle is shaped as and is followed successively by cylinder+sphere+cylinder from top to bottom, and wherein the cylinder of hypomere is littler than epimere body diameter.
4. oxytocin nasal spray as claimed in claim 1, the inner bag that it is characterized in that described spray bottle is shaped as cylinder+eggplant shape as shown in Figure 2.
5. oxytocin nasal spray as claimed in claim 1, the inner bag that it is characterized in that described spray bottle is shaped as cylinder+sphere+cylinder as shown in Figure 3, and wherein the cylinder of hypomere is littler than epimere body diameter, and end portion is hemisphere.
6. oxytocin nasal spray as claimed in claim 1, described sprayer unit comprises spray bottle and fog-spray nozzle, the shell that it is characterized in that described spray bottle has profile, size and the interface section identical with the spray bottle of existing commercially available 10ml spray device, and fog-spray nozzle adopts the fog-spray nozzle of existing commercially available 10ml spray device.
7. oxytocin nasal spray as claimed in claim 6, the inner bag shape of described spray bottle is followed successively by cylinder+eggplant shape from top to bottom.
8. oxytocin nasal spray as claimed in claim 6, the inner bag shape of described spray bottle is followed successively by cylinder+sphere+cylinder from top to bottom, and wherein the cylinder of hypomere is littler than epimere body diameter, and end portion is hemisphere.
9. oxytocin nasal spray as claimed in claim 6 is characterized in that sprayer unit as shown in Figure 4, and the inner bag shape of spray bottle is followed successively by cylinder+eggplant shape from top to bottom.
10. oxytocin nasal spray as claimed in claim 6, it is characterized in that described sprayer unit as shown in Figure 5, the inner bag shape of spray bottle is followed successively by cylinder+sphere+cylinder from top to bottom, and wherein the cylinder of hypomere is littler than epimere body diameter, and end portion is hemisphere.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100399972A CN103285473A (en) | 2012-02-22 | 2012-02-22 | Oxytocin nasal spray |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100399972A CN103285473A (en) | 2012-02-22 | 2012-02-22 | Oxytocin nasal spray |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103285473A true CN103285473A (en) | 2013-09-11 |
Family
ID=49087350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100399972A Pending CN103285473A (en) | 2012-02-22 | 2012-02-22 | Oxytocin nasal spray |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103285473A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001089984A1 (en) * | 2000-05-23 | 2001-11-29 | Carter-Wallace, Inc. | Dispensing container |
| CN2495380Y (en) * | 2001-08-09 | 2002-06-19 | 田霞 | Sprayer |
| CN2687018Y (en) * | 2003-12-10 | 2005-03-23 | 袁航宇 | Bottle with bottle cap |
| CN2707631Y (en) * | 2004-05-24 | 2005-07-06 | 巢晓峰 | Internal bladder tube made glass bottle |
| CN2915696Y (en) * | 2005-12-15 | 2007-06-27 | 云南盘龙云海药业有限公司 | Packaging bottle |
| WO2009115200A1 (en) * | 2008-03-17 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Reservoir and nebulizer |
| WO2010040979A1 (en) * | 2008-10-08 | 2010-04-15 | Archimedes Development Ltd. | A device for administering liquid analgesics |
-
2012
- 2012-02-22 CN CN2012100399972A patent/CN103285473A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001089984A1 (en) * | 2000-05-23 | 2001-11-29 | Carter-Wallace, Inc. | Dispensing container |
| CN2495380Y (en) * | 2001-08-09 | 2002-06-19 | 田霞 | Sprayer |
| CN2687018Y (en) * | 2003-12-10 | 2005-03-23 | 袁航宇 | Bottle with bottle cap |
| CN2707631Y (en) * | 2004-05-24 | 2005-07-06 | 巢晓峰 | Internal bladder tube made glass bottle |
| CN2915696Y (en) * | 2005-12-15 | 2007-06-27 | 云南盘龙云海药业有限公司 | Packaging bottle |
| WO2009115200A1 (en) * | 2008-03-17 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Reservoir and nebulizer |
| WO2010040979A1 (en) * | 2008-10-08 | 2010-04-15 | Archimedes Development Ltd. | A device for administering liquid analgesics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN204275273U (en) | A kind of Respiratory Medicine medicinal sprayer | |
| CN103285469A (en) | Desmopressin acetate nasal spraying agent | |
| CN103285473A (en) | Oxytocin nasal spray | |
| CN206026856U (en) | Ware of dosing with scalable denture fixing device | |
| CN103285472A (en) | Ketorolac tromethamine nasal spray | |
| CN103285467A (en) | Nafarelin acetate nasal spraying agent | |
| CN214260337U (en) | Gynecological clinical drug delivery device | |
| CN210844937U (en) | Integrated cleaning drug administration sprayer | |
| CN103285470A (en) | Metoclopramide nasal spray | |
| CN202213866U (en) | Spray bottle for small-volume spraying device and small-volume spraying device using same | |
| CN209075826U (en) | Chemical spraying device is used in a kind of nursing of ear-nose-throat department | |
| CN103285474A (en) | Sumatriptan nasal spray | |
| CN203291330U (en) | Medicine spraying device for otorhinolaryngological nursing | |
| CN219126851U (en) | Livestock and veterinary medicine filling device | |
| CN102805891A (en) | Spray bottle for small-capacity spray device | |
| CN214910749U (en) | a nasal feeding device | |
| CN103285471A (en) | Vitamin B12 nasal spray | |
| CN222174333U (en) | Tablet grinding and drug delivery device | |
| CN104258498A (en) | Convenient quantitative sprayer for powder drugs | |
| CN103285477A (en) | Dihydroergotamine mesilate nasal spray | |
| CN2728527Y (en) | Pneumatic medicine sprayer for throat | |
| CN204307166U (en) | The hand-held atomized medicine sprayer of department of pediatrics | |
| CN218202137U (en) | Filling device is used in production of medicine bulk drug | |
| CN1385165A (en) | Ribavirin aerosol inhalation solution | |
| CN2621704Y (en) | Throat sprayer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING TIANHENG HOSPITAL MANAGEMENT CO., LTD. Free format text: FORMER OWNER: BEIJING TIANHENG MEDICINE INST. Effective date: 20150203 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100141 FENGTAI, BEIJING TO: 100070 FENGTAI, BEIJING |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150203 Address after: 100070, room 25, building 188, No. eighteen, 407 West Fourth Ring Road, Fengtai District, Beijing Applicant after: Beijing Tianheng Hospital Management Co. Ltd. Address before: 100141 Beijing City, Fengtai District Jiang Jia Fen No. 329 Beijing Tianheng Pharmaceutical Institute Applicant before: Beijing Tianheng Medicine Inst. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170512 Address after: 100141 Beijing city Fengtai District Xiaotun Road No. 8 purple Park office block C C510 Applicant after: Beijing Tianheng Pharmaceutical Research Institute Co. Ltd. Address before: 100070, room 25, building 188, No. eighteen, 407 West Fourth Ring Road, Fengtai District, Beijing Applicant before: Beijing Tianheng Hospital Management Co. Ltd. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130911 |